SequelSEC

60 DEGREES PHARMACEUTICALS, INC. SXTP

Pharmaceutical Preparations · CIK 0001946563 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$207.90K
Fiscal year ended 2026-06-30
Operating income
-$2.27M
Fiscal year ended 2026-06-30
Free cash flow
-$2.23M
Fiscal year ended 2026-06-30

60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported revenue of $207.90K and net income of -$2.26M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from 60 DEGREES PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

60 DEGREES PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$207.90K$162.09K$303.38K$437.60K$100.93K$163.55K$241.64K$135.29K$124.97K$105.67K
Cost of revenue$151.10K$85.72K$120.68K$537.69K$50.05K$73.27K$118.08K$111.69K$89.56K$65.44K
Gross profit$56.80K$76.38K$182.70K-$100.09K$50.88K$90.28K$123.56K$23.61K$35.41K$40.24K
Operating income-$2.27M-$2.09M-$1.92M-$2.33M-$1.61M-$1.91M-$2.07M-$2.12M-$4.19M-$1.34M
Net income-$2.26M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.05M-$2.16M-$4.17M$430.47K
Research & development$598.65K$281.46K$638.87K$809.78K$231.91K$370.81K$613.96K$940.06K$3.10M$337.18K
Weighted-average diluted sharesshares 2.65Mshares 1.73MUnavailableshares 3.68MUnavailableUnavailableUnavailableshares 2.15MUnavailableUnavailable
Pretax income-$2.27M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.05M-$2.16M-$4.17M$428.05K
Income tax expenseUnavailableUnavailable-$1.81K$250$1.50K$63-$751$250$438$63
Diluted EPS$-0.90$-1.28Unavailable$-0.66$-5.01$-6.25Unavailable$-2.92$-21.12$1.83
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.73M$1.89M$1.47M$1.51M$1.63M$1.72M$1.61M$1.22M$1.13M$1.08M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

60 DEGREES PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$1.02M$3.34M$1.51M$4.12M$1.97M$3.45M$1.66M$3.30M$1.58MUnavailable
Total assets$4.28M$6.76M$5.37M$6.69M$4.18M$5.98M$5.76M$7.42M$4.33M$8.38M
Current assets$3.73M$6.26M$4.90M$6.31M$3.84M$5.65M$5.39M$6.89M$3.76M$7.91M
Total liabilities$1.75M$2.02M$1.99M$2.34M$1.84M$1.95M$1.80M$1.46M$1.37M$1.25M
Current liabilities$1.61M$1.88M$1.84M$2.20M$1.69M$1.80M$1.66M$1.31M$1.22M$1.10M
Total equity incl. NCI$2.53M$4.74M$3.38M$4.35M$2.35M$4.03M$3.96M$5.96M$2.96M$7.13M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$877.94K$910.60K$656.92K$527.00K$799.42K$773.24K$442.76K$452.04K$426.02K$435.38K
Accounts receivable$567.04K$335.84K$509.64K$674.04K$295.03K$488.24K$486.75K$323.82K$296.37K$316.22K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$150.03K$150.03K$144.00K$150.00K$150.00K$150.00K$147.12K$150.00K$150.00K$150.00K
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

60 DEGREES PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$2.23M-$2.74M-$1.69M-$2.11M-$1.45M-$1.60M-$1.64M-$1.68M-$1.19M-$1.14M
Capital expenditures$0$30.00K$79.88K$10.00K$47.32K$2.68K$0$13.77KUnavailableUnavailable
Investing cash flow-$85.98K$1.19M-$1.37M-$25.49K-$51.68K$1.70M-$2.10K-$1.75M-$130.56K-$9.81K
Financing cash flow$0$3.37M$458.61K$4.28M$0$1.70M$973$5.15M-$865$1.90M
Net change in cash-$2.32M$1.83M-$2.61M$2.15M-$1.48M$1.79M-$1.64M$1.72M-$1.32M$752.22K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$16.95K$16.70K$15.17K$12.22K$9.24K$6.69K$5.45K$4.33K$1.54K$407

Derived

60 DEGREES PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$2.23M-$2.77M-$1.77M-$2.12M-$1.50M-$1.60M-$1.64M-$1.69MUnavailableUnavailable
Gross margin27.3%47.1%60.2%-22.9%50.4%55.2%51.1%17.4%28.3%38.1%
Operating margin-1092.4%-1292.5%-632.0%-531.4%-1591.5%-1168.4%-854.7%-1566.0%-3351.8%-1270.4%
FCF margin-1073.5%-1709.9%-584.2%-484.2%-1483.6%-978.3%-678.0%-1252.8%UnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.32x3.34x2.66x2.87x2.27x3.13x3.25x5.26x3.09x7.16x
Revenue YoY growth106.0%-0.9%25.6%223.4%-19.2%54.8%92.3%164.3%109.9%515.4%
Net margin-1089.2%-1288.9%-474.2%-529.3%-1717.7%-1147.4%-846.3%-1596.4%-3339.0%407.4%
R&D / revenue288.0%173.6%210.6%185.0%229.8%226.7%254.1%694.8%2476.8%319.1%
CapEx / revenue0.0%18.5%26.3%2.3%46.9%1.6%0.0%10.2%UnavailableUnavailable
Long-term debt / equity0.06xUnavailableUnavailable0.03xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SXTP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-06-30

Difference 1836092 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.